Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by <i>Plasmodium falciparum</i> Genotype.

ABSTRACT: The first-line treatments for uncomplicated Plasmodium falciparum malaria are artemisinin-based combination therapies (ACTs), consisting of an artemisinin derivative combined with a longer acting partner drug. However, the spread of P. falciparum with decreased susceptibility to artemisinin and partner drugs presents a significant challenge to malaria control efforts. To stem the spread of drug resistant parasites, novel chemotherapeutic strategies are being evaluated, including the implementation of triple artemisinin-based combination therapies (TACTs). Currently, there is limited knowledge on the pharmacodynamic and pharmacogenetic interactions of proposed TACT drug combinations. To evaluate these interactions, we established an in vitro high-throughput process for

SUBMITTER: Ansbro MR 

PROVIDER: S-EPMC7737215 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature